Vivos Therapeutics signals transformative growth with SCN acquisition and expects positive cash flow by end of 2025

May 15, 2025 7:32 PM ETVivos Therapeutics, Inc. (VVOS) StockAI-Generated Earnings Calls Insights
(8min)

Earnings Call Insights: Vivos Therapeutics (VVOS) Q1 2025

Management View

  • CEO Kirk Huntsman described the first quarter as an inflection point, highlighting a strategic transition to alliances and acquisitions of sleep medical providers. He stated, "This pivot is less than a year old
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Recommended For You

More Trending News

About VVOS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VVOS--
Vivos Therapeutics, Inc.